ORGANICELL REGENERATIVE MEDICINE, INC. : Other Events, Financial Statements and Exhibits (form 8-K)

Item 8.01 Other Events.

On April 21, 2021, Organicell issued a press release in which it announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for its lead product, Zofin™, in the treatment of knee osteoarthritis.

A copy of the Company's press release dated April 21, 2021 is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits



Exhibit No   Description

   99.1        Press Release, dated April 21, 2021




                                       1

© Edgar Online, source Glimpses